What Evidence is Essential for New Medical Products?
Implications for Patients and Health Policy

June 13, 2014
AAAS Headquarters
Washington

Conference AAAS Article
Conference Health Affairs Blog Entry
Bibliography of Key Articles
Conference Agenda
Speaker Biographies

Sponsoring Organizations

This event is co-sponsored by the American Association for the Advancement of Science, the Division of Pharmacoepidemiology and Pharmacoeconomics of Brigham and Women’s Hospital/Harvard Medical School, and the National Center for Health Research.

About AAAS

The American Association for the Advancement of Science (AAAS) is the world’s largest general scientific society and publisher of the journal Science as well as Science Translational Medicine and Science Signaling. AAAS was founded in 1848 and includes some 262 affiliated societies and academies of science, serving 10 million individuals. Science has the largest paid circulation of any peer-reviewed general science journal in the world, with an estimated total readership of 1 million. The non-profit AAAS is open to all and fulfills its mission to “advance science and serve society” through initiatives in science policy; international programs; science education; and more. For the latest research news, log onto EurekAlert! the premier science-news website, a service of AAAS.

About the Division of Pharmacoepidemiology and Pharmacoeconomics of Brigham and Women’s Hospital/Harvard Medical School

The Division of Pharmacoepidemiology and Pharmacoeconomics—which is part of the Department of Medicine at Brigham and Women’s Hospital (BWH), a teaching hospital of Harvard Medical School—facilitates a wide range of activities related to the use and outcomes of medications, addressed from a variety of interdisciplinary perspectives. Its mission is to bring together the various specialties of medicine, epidemiology, biostatistics, health services research, and the social sciences to evaluate the effectiveness of existing and new prescription drugs in relation to their risks and costs; to study how medications are used by physicians and patients; and to develop methods to optimize prescription drug use. Within the Division, the Program On Regulation, Therapeutics, And Law (PORTAL) engages in research and training that considers how laws and regulations influence the development, utilization, and affordability of therapeutics, as well as the ethical questions these issues raise for patients, physicians, policymakers, and payors.

About the National Center for Health Research

The National Center for Health Research uses scientific evidence to promote the health of men, women, and children through more effective programs and policies. The Center achieves its mission by conducting research, analyzing and scrutinizing information, and explaining the implications of the findings for patients and public health. The Center provides information for free to the public, the media, opinion leaders, and policy makers. In addition to helping individuals, the Center works on the local, state, and national level to inform policies with implications for human health. Center staff testify before the U.S. Congress; federal agencies such as the Food and Drug Administration, the Centers for Disease Control and Prevention, and the Environmental Protection Agency; and state legislators about the strength and weaknesses of programs and policies, and about the comparative safety and effectiveness of medicines and other products in our homes and communities.

Outside funding for the conference is provided by a Robert Wood Johnson Investigator Award in Health Policy Research (Dr. Kesselheim), by the Greenwall Foundation Faculty Scholars Program (Dr. Kesselheim), and the Patient-Centered Outcomes Research Institute (PCORI) through the Eugene Washington PCORI Engagement Awards Program.